162 related articles for article (PubMed ID: 35798094)
21. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
22. Enhanced anti-tumor activity of a drug through pH-triggered release and dual targeting by calcium phosphate-covered mesoporous silica vehicles.
Liu J; Hu X; Jin S; Liang XJ; Ma X
J Mater Chem B; 2022 Jan; 10(3):384-395. PubMed ID: 34935843
[TBL] [Abstract][Full Text] [Related]
23. Fluorescent carbon dot modified mesoporous silica nanocarriers for redox-responsive controlled drug delivery and bioimaging.
Jiao J; Liu C; Li X; Liu J; Di D; Zhang Y; Zhao Q; Wang S
J Colloid Interface Sci; 2016 Dec; 483():343-352. PubMed ID: 27569517
[TBL] [Abstract][Full Text] [Related]
24. pH-Sensitive drug delivery system based on modified dextrin coated mesoporous silica nanoparticles.
Chen H; Zheng D; Liu J; Kuang Y; Li Q; Zhang M; Ye H; Qin H; Xu Y; Li C; Jiang B
Int J Biol Macromol; 2016 Apr; 85():596-603. PubMed ID: 26776872
[TBL] [Abstract][Full Text] [Related]
25. Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy.
Wei Y; Gao L; Wang L; Shi L; Wei E; Zhou B; Zhou L; Ge B
Drug Deliv; 2017 Nov; 24(1):681-691. PubMed ID: 28414557
[TBL] [Abstract][Full Text] [Related]
26. Effect of pH-responsive alginate/chitosan multilayers coating on delivery efficiency, cellular uptake and biodistribution of mesoporous silica nanoparticles based nanocarriers.
Feng W; Nie W; He C; Zhou X; Chen L; Qiu K; Wang W; Yin Z
ACS Appl Mater Interfaces; 2014 Jun; 6(11):8447-60. PubMed ID: 24745551
[TBL] [Abstract][Full Text] [Related]
27. Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery.
Al-Nadaf AH; Dahabiyeh LA; Jawarneh S; Bardaweel S; Mahmoud NN
Pharm Dev Technol; 2021 Jun; 26(5):582-591. PubMed ID: 33729906
[TBL] [Abstract][Full Text] [Related]
28. Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
Zou Z; He D; He X; Wang K; Yang X; Qing Z; Zhou Q
Langmuir; 2013 Oct; 29(41):12804-10. PubMed ID: 24073830
[TBL] [Abstract][Full Text] [Related]
29. Egg-yolk core-shell mesoporous silica nanoparticles for high doxorubicin loading and delivery to prostate cancer cells.
Tiburcius S; Krishnan K; Jose L; Patel V; Ghosh A; Sathish CI; Weidenhofer J; Yang JH; Verrills NM; Karakoti A; Vinu A
Nanoscale; 2022 May; 14(18):6830-6845. PubMed ID: 35441642
[TBL] [Abstract][Full Text] [Related]
30. Poly(amino acid)/ZnO/mesoporous silica nanoparticle based complex drug delivery system with a charge-reversal property for cancer therapy.
Kuang Y; Chen H; Chen Z; Wan L; Liu J; Xu Z; Chen X; Jiang B; Li C
Colloids Surf B Biointerfaces; 2019 Sep; 181():461-469. PubMed ID: 31176118
[TBL] [Abstract][Full Text] [Related]
31. A comparison of mesoporous silica nanoparticles and mesoporous organosilica nanoparticles as drug vehicles for cancer therapy.
Yue J; Luo SZ; Lu MM; Shao D; Wang Z; Dong WF
Chem Biol Drug Des; 2018 Aug; 92(2):1435-1444. PubMed ID: 29671941
[TBL] [Abstract][Full Text] [Related]
32. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe
Fang Z; Li X; Xu Z; Du F; Wang W; Shi R; Gao D
Int J Nanomedicine; 2019; 14():5785-5797. PubMed ID: 31440047
[No Abstract] [Full Text] [Related]
33. Enhanced Blood Suspensibility and Laser-Activated Tumor-specific Drug Release of Theranostic Mesoporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes.
Su J; Sun H; Meng Q; Zhang P; Yin Q; Li Y
Theranostics; 2017; 7(3):523-537. PubMed ID: 28255347
[TBL] [Abstract][Full Text] [Related]
34. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
35. Mixed shell mesoporous silica nanoparticles for controlled drug encapsulation and delivery.
Wu Q; Hou Y; Han G; Liu X; Tang X; Li H; Song X; Zhang G
Nanomedicine (Lond); 2017 Nov; 12(22):2699-2711. PubMed ID: 28967827
[TBL] [Abstract][Full Text] [Related]
36. Charge-Reversal APTES-Modified Mesoporous Silica Nanoparticles with High Drug Loading and Release Controllability.
Wang Y; Sun Y; Wang J; Yang Y; Li Y; Yuan Y; Liu C
ACS Appl Mater Interfaces; 2016 Jul; 8(27):17166-75. PubMed ID: 27314423
[TBL] [Abstract][Full Text] [Related]
37. A carboxymethyl lentinan layer by layer self-assembly system as a promising drug chemotherapeutic platform.
Cai D; Shi L; Long R; Ren G; Wang S; Liu Y
Carbohydr Polym; 2021 Jun; 261():117847. PubMed ID: 33766343
[TBL] [Abstract][Full Text] [Related]
38. Amino-functionalized mesoporous silica nanoparticles as efficient carriers for anticancer drug delivery.
He Y; Luo L; Liang S; Long M; Xu H
J Biomater Appl; 2017 Oct; 32(4):524-532. PubMed ID: 28776488
[TBL] [Abstract][Full Text] [Related]
39. Controlled synthesis and size effects of multifunctional mesoporous silica nanosystem for precise cancer therapy.
Ma B; He L; You Y; Mo J; Chen T
Drug Deliv; 2018 Nov; 25(1):293-306. PubMed ID: 29334793
[TBL] [Abstract][Full Text] [Related]
40. Aptamer-modified chitosan-capped mesoporous silica nanoparticles for co-delivery of cytarabine and daunorubicin in leukemia.
Heydari SR; Ghahremani MH; Atyabi F; Bafkary R; Jaafari MR; Dinarvand R
Int J Pharm; 2023 Nov; 646():123495. PubMed ID: 37806507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
